Sabra Health Care REIT Inc
NASDAQ:SBRA
Intrinsic Value
Sabra Health Care REIT, Inc. engages in managing and investing in healthcare-related real estate properties. [ Read More ]
The intrinsic value of one
SBRA
stock under the Base Case scenario is
16.4
USD.
Compared to the current market price of 13.65 USD,
Sabra Health Care REIT Inc
is
Undervalued by 17%.
Sabra Health Care REIT Inc's market capitalization is 3.2B USD.
SBRA stock price is 13.65 USD.
SBRA stock price (13.65 USD) is 17% less than its Intrinsic Value (16.4 USD).
SBRA stock price (13.65 USD) is 43% less than its Relative Value (23.85 USD). Open Relative Valuation
SBRA has upside potential of 19% compared to the average analyst price target.
Open Wall St Estimates
SBRA's ROIC (Return on Invested Capital) has decreased in the last 3 years from 4% to 4%.
SBRA's Revenue has grown by 4% over the past 12 months.
SBRA's Revenue has been growing by 3% per year for the last 3 years.
SBRA's Revenue is forecast to grow at a rate of 4% per year over the next 3 years.
SBRA's ROE (Return on Equity) has decreased in the last 3 years from 4% to 0%.
SBRA's ROIC (Return on Invested Capital) for the past 12 months is very low and is equal to 4%.
SBRA's short-term assets (175m USD) exceed its short-term liabilties (137m USD).
SBRA's ROE (Return on Equity) for the past 12 months is very low and is equal to 0%.
SBRA's D/E (Debt to Equity) is very low and is equal to 0.86.
SBRA has a very low three-year average ROIC (Return on Invested Capital): 4%. The company is not efficient at using invested capital to generate operating income.
SBRA has positive Net Income for the last twelve months.
SBRA's long-term assets (5B USD) exceed its long-term liabilties (3B USD).
SBRA has negative three-year average ROE (Return on Equity): -1%. The company is not efficient at transforming stockholders' equity into net income.
SBRA has positive Operating Income for the last twelve months.
SBRA has positive Gross Profit for the last twelve months.
SBRA has positive Free Cash Flow for the last twelve months.
SBRA has positive Net Debt. This means that the company has more debt (2B USD) than cash and short-term investments (41m USD).
SBRA's Altman Z-Score is very low and is equal to 0.58.
SBRA generates enough operating income (222m USD) to cover interest payments on its debt (102m USD).
Valuation Backtest
Sabra Health Care REIT Inc
Run backtest to discover the historical profit from buying and selling
SBRA
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Sabra Health Care REIT Inc
Balance Sheet Decomposition
Sabra Health Care REIT Inc
| Current Assets | 175.1m |
| Cash & Short-Term Investments | 41.3m |
| Receivables | 133.8m |
| Non-Current Assets | 5.2B |
| Long-Term Investments | 194.7m |
| PP&E | 4.6B |
| Intangibles | 30.9m |
| Other Non-Current Assets | 368.2m |
| Current Liabilities | 137m |
| Accounts Payable | 120.5m |
| Accrued Liabilities | 16.5m |
| Non-Current Liabilities | 2.4B |
| Long-Term Debt | 2.4B |
| Other Non-Current Liabilities | 32.5m |
Earnings Waterfall
Sabra Health Care REIT Inc
|
Revenue
|
647.5m
USD
|
|
Cost of Revenue
|
-177.3m
USD
|
|
Gross Profit
|
470.2m
USD
|
|
Operating Expenses
|
-248.7m
USD
|
|
Operating Income
|
221.5m
USD
|
|
Other Expenses
|
-207.8m
USD
|
|
Net Income
|
13.8m
USD
|
Free Cash Flow Analysis
Sabra Health Care REIT Inc
SBRA Profitability Score
Profitability Due Diligence
Sabra Health Care REIT Inc's profitability score is 54/100. The higher the profitability score, the more profitable the company is.
Score
Sabra Health Care REIT Inc's profitability score is 54/100. The higher the profitability score, the more profitable the company is.
SBRA Solvency Score
Solvency Due Diligence
Sabra Health Care REIT Inc's solvency score is 30/100. The higher the solvency score, the more solvent the company is.
Score
Sabra Health Care REIT Inc's solvency score is 30/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SBRA Price Targets Summary
Sabra Health Care REIT Inc
According to Wall Street analysts, the average 1-year price target for
SBRA
is 16.23 USD
with a low forecast of 14.14 USD and a high forecast of 22.05 USD.
Ownership
SBRA Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
SBRA Price
Sabra Health Care REIT Inc
| Average Annual Return | -2.59% |
| Standard Deviation of Annual Returns | 12.44% |
| Max Drawdown | -75% |
| Market Capitalization | 3.2B USD |
| Shares Outstanding | 233 200 180 |
| Percentage of Shares Shorted | 6.94% |
Company Profile
Sabra Health Care REIT Inc
Country
Industry
Market Cap
Dividend Yield
Description
Sabra Health Care REIT, Inc. engages in managing and investing in healthcare-related real estate properties. The company is headquartered in Irvine, California and currently employs 42 full-time employees. The company went IPO on 2010-11-06. The firm through its subsidiaries, owns and invests in real estate serving the healthcare industry. Its primary business consists of acquiring, financing, and owning real estate property to be leased to third-party tenants in the healthcare sector. The company is engaged in leasing properties to tenants and owning properties operated by third-party property managers throughout the United States and Canada. The Company’s investment portfolio is primarily comprised of skilled nursing/transitional care facilities, senior housing communities and specialty hospitals and other facilities, in each case leased to third-party operators; senior housing communities operated by third-party property managers pursuant to property management agreements; investments in loans receivable, and preferred equity investments.
Contact
IPO
Employees
Officers
The intrinsic value of one
SBRA
stock under the Base Case scenario is
16.4
USD.
Compared to the current market price of 13.65 USD,
Sabra Health Care REIT Inc
is
Undervalued by 17%.
You don't have any saved screeners yet
